Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Core Viewpoint - Incannex Healthcare Inc. has regained compliance with Nasdaq's minimum bid price requirement, which allows the company to continue its listing on the Nasdaq Capital Market [1][2][3] Company Compliance - The company received confirmation from Nasdaq that its common stock maintained a closing bid price of $1.00 or greater for eleven consecutive business days from February 27 to March 13, 2026, thus satisfying the listing requirements [2] Financial Position - Incannex Healthcare has approximately $75 million in cash and no debt, positioning the company well to advance its clinical programs [3] Clinical Development - The company is focused on advancing its pipeline, including IHL-42X for obstructive sleep apnea, which has shown statistically significant Phase 2 results, and PSX-001 for generalized anxiety disorder, which has also produced positive clinical outcomes [3][4] Product Pipeline - Incannex is developing combination medicines targeting chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder, with three clinical-stage product candidates [4]